cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection

RxCUI: 2184142
RxNorm name: cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection
Display name: cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection
Full name: cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:39:19

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
RECARBRIO	IMIPENEM ANHYDROUS, CILASTATIN, AND RELEBACTAM ANHYDROUS	Merck Sharp & Dohme LLC	be32f468-738b-40df-a425-591e12f65159	2025-12-09	Warnings, Adverse reactions	Exact identifier rxcui: 2184142

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
be32f468-738b-40df-a425-591e12f65159	cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection	SCD	11	These highlights do not include all the information needed to use RECARBRIO safely and effectively. See full prescribing information for RECARBRIO. RECARBRIO ® (imipenem, cilastatin, and relebactam) for injection, for intravenous use Initial U.S. Approval: 2019	20251209
be32f468-738b-40df-a425-591e12f65159	cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection	PSN	11	These highlights do not include all the information needed to use RECARBRIO safely and effectively. See full prescribing information for RECARBRIO. RECARBRIO ® (imipenem, cilastatin, and relebactam) for injection, for intravenous use Initial U.S. Approval: 2019	20251209